These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32996696)

  • 1. Risk factors correlated with immunosuppressant discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis patients.
    Murosaki T; Sato T; Nagatani K; Sato K; Minota S
    Int J Rheum Dis; 2020 Nov; 23(11):1587-1593. PubMed ID: 32996696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database.
    Sakai R; Tanaka E; Nishina H; Suzuki M; Yamanaka H; Harigai M
    Int J Rheum Dis; 2019 Nov; 22(11):1978-1984. PubMed ID: 31338986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort.
    Shi YY; Li ZY; Zhao MH; Chen M
    Medicine (Baltimore); 2015 May; 94(18):e843. PubMed ID: 25950695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
    Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
    PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance treatment of ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):199-201. PubMed ID: 28406765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Morishita M; Sada KE; Matsumoto Y; Hayashi K; Asano Y; Hiramatsu Asano S; Ohashi K; Miyawaki Y; Katsuyama E; Watanabe H; Kawabata T; Wada J
    PLoS One; 2019; 14(7):e0218705. PubMed ID: 31291263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
    Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
    Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
    Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
    BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
    Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
    Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
    Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
    Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
    Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
    Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
    Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
    Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Fujimoto S; Dobashi H; Yuzawa Y; Yamagata K; Muso E; Arimura Y; Makino H
    Mod Rheumatol; 2021 Jan; 31(1):205-213. PubMed ID: 31859544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
    Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
    Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
    McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.